Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.75 |
| ▸ | KIT | P10721 | 12/20 | 0.67 |
| ▸ | FLT3 | P36888 | 12/20 | 0.67 |
| ▸ | CSF1R | P07333 | 6/20 | 0.67 |
| ▸ | LCK | P06239 | 5/20 | 0.67 |
| ▸ | LYN | P07948 | 5/20 | 0.67 |
| ▸ | SRC | P12931 | 5/20 | 0.67 |
| ▸ | FLT4 | P35916 | 5/20 | 0.67 |
| ▸ | BLK | P51451 | 5/20 | 0.67 |
| ▸ | FLT1 | P17948 | 5/20 | 0.67 |
| ▸ | ABL1 | P00519 | 3/20 | 0.67 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.64 |
| ▸ | FYN | P06241 | 5/20 | 0.57 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.55 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.55 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2236868 | 0.89 | KDR (0.60) | KDRKITFLT3CSF1RLCK | |
| SCHEMBL1703109 | 0.86 | KDR (0.74) | KDRKITFLT3CSF1RLCK | |
| SCHEMBL1703083 | 0.86 | KDR (0.74) | KDRKITFLT3CSF1RLCK | |
| SCHEMBL1703063 | 0.86 | KDR (0.77) | KDRKITFLT3CSF1RLCK | |
| SCHEMBL1702788 | 0.85 | KDR (0.76) | KDRKITFLT3CSF1RLCK | |
| SCHEMBL425326 | 0.84 | KDR (0.75) | KDRKITFLT3CSF1RLCK | |
| SCHEMBL1702977 | 0.84 | KDR (0.75) | KDRKITFLT3CSF1RLCK | |
| SCHEMBL420525 | 0.84 | KDR (0.63) | KDRKITFLT3CSF1RLCK | |
| SCHEMBL422215 | 0.83 | KDR (0.62) | KDRKITFLT3CSF1RLCK | |
| SCHEMBL1702906 | 0.83 | KDR (0.72) | KDRKITFLT3CSF1RLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807424-B1 | NOVEL KINASE INHIBITORS | ABBOTT LAB (US) | 2012-04-18 | — | — | EP | claimed |
| EP-1807424-A2 | NOVEL KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2007-07-18 | — | — | EP | claimed |
| US-20060178378-A1 | Novel kinase inhibitors | ABBVIE INC. | 2006-08-10 | — | — | US | claimed |
| WO-2006050109-A2 | NOVEL KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2006-05-11 | — | — | WO | claimed |
| EP-1807424-B1 | NOVEL KINASE INHIBITORS | ABBOTT LAB (US) | 2012-04-18 | — | — | EP | disclosed |
| US-7812166-B2 | Kinase inhibitors | ABBOTT LABORATORIES (US) | 2010-10-12 | — | — | US | disclosed |
| US-20060178378-A1 | Novel kinase inhibitors | ABBVIE INC. | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178378-A1 | Novel kinase inhibitors | ABL1, MAP3K19, MAP3K20 | KDR 434/4885KIT 426/4885FLT3 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.